Remifentanil-based sedation to treat noninvasive ventilation failure: a preliminary study
- First Online:
- Cite this article as:
- Constantin, JM., Schneider, E., Cayot-Constantin, S. et al. Intensive Care Med (2007) 33: 82. doi:10.1007/s00134-006-0447-4
- 348 Downloads
To assess the feasibility and safety of remifentanil-based sedation during noninvasive ventilation (NIV) in patients with NIV failure.
Design and setting
Prospective clinical investigation in a 16-bed intensive care unit of a university hospital in France.
Thirteen patients in NIV failure due to discomfort and/or refusal to continue this ventilatory support: 10 with acute respiratory failure and 3 with acute hypercapnic respiratory failure.
Patients were administered methylene blue and were sedated (Ramsay scale 2–3) by a continuous perfusion of remifentanil during NIV. Cardiorespiratory and ventilatory parameters, blood gas analysis, and adverse events were prospectively recorded.
Measurements and results
The 13 patients received a total of 125 NIV sessions, totaling 1200 h, of NIV under remifentanil-based sedation (mean remifentanil dose 0.1 ± 0.03 μg/kg per minute). Three patients also required propofol. PaO2/FIO2 ratio increased from 134 ± 69 to 187 ± 43 mmHg after 1 h. In patients with acute respiratory failure respiratory rate decreased from 34 ± 12 per minute before remifentanil to 25 ± 4 per minute after 1 h. In the three patients with acute hypercapnic respiratory failure PaCO2 decreased from 69 ± 7 to 42 ± 5 mmHg. Four patients required endotracheal intubation without aspiration pneumonia. Twelve of the 13 patients left the ICU.
This pilot study shows that remifentanil-based sedation is safe and effective in the treatment of NIV failure due to low tolerance.